Cart
sales@molnova.com
Olaratumab
CAS No. 1024603-93-7
Olaratumab( —— )
Catalog No. M36704 CAS No. 1024603-93-7
Olaratumab(IMC-3G3) is a human monoclonal IgG1 antibody against platelet-derived growth factor receptor alpha (PDGFRα), which has antitumor effects and can be used to study advanced soft tissue sarcomas.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 2MG | 375 | Get Quote |
|
| 5MG | 613 | Get Quote |
|
| 10MG | 938 | Get Quote |
|
| 25MG | 1408 | Get Quote |
|
| 50MG | 1822 | Get Quote |
|
| 100MG | 2511 | Get Quote |
|
| 500MG | Get Quote | Get Quote |
|
| 1G | Get Quote | Get Quote |
|
Biological Information
-
Product NameOlaratumab
-
NoteResearch use only, not for human use.
-
Brief DescriptionOlaratumab(IMC-3G3) is a human monoclonal IgG1 antibody against platelet-derived growth factor receptor alpha (PDGFRα), which has antitumor effects and can be used to study advanced soft tissue sarcomas.
-
DescriptionOlaratumab (IMC-3G3; LY3012207) is an anti-platelet-derived growth factor receptor alpha (PDGFRα) human monoclonal IgG1 antibody with antitumor activity.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayAngiogenesis
-
TargetPDGFR
-
RecptorPDGFR
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number1024603-93-7
-
Formula Weight
-
Molecular Formula——
-
Purity>98% (HPLC)
-
Solubility——
-
SMILES——
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Koji Matsuo, et al. Platelet-derived growth factor receptor alpha (PDGFRα) targeting and relevant biomarkers in ovarian carcinoma. Gynecol Oncol. 2014 Jan;132(1):166-75.??
molnova catalog
related products
-
PDGFRα kinase inhibi...
PDGFRα kinase inhibitor 1 is a highly selective inhibitor of type II PDGFRα kinase (PDGFRα and PDGFRβ) with IC50 values of 132 nM and 6115 nM, respectively.
-
Regorafénib N-oxyde ...
Regorafénib N-oxyde M2 is an active metabolite of Regorafenib. Regorafenib is a multi-target inhibitor for VEGFR1/2/3, PDGFRβ, RET, Kit, and Raf-1.
-
TSU-68
TSU-68 (Orantinib, SU6668) is a small-molecule, ATP-competitiv inhibitor of angiogenic related RTKs KDR, PDGFRβ, FGFR1.
